NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it has signed an agreement to develop and commercialize a next-generation sequencing-based companion diagnostic for Agios Pharmaceuticals' investigational cancer drug ivosidenib.

Ivosidenib is an inhibitor of isocitrate dehydrogenase 1 (IDH1), which is mutated in various cancers. It is currently in Phase III testing in patients with cholangiocarcinoma — a rare cancer of the bile duct system — who harbor IDH1 mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.